5 курс / Психиатрия и наркология для детей и взрослых (доп.) / Клиническая_психофармакогенетика_Р_Ф_Насырова,_Н_Г
.pdfГлава 8. ФАРМАКОГЕНЕТИКА ПРОТИВОЭПИЛЕПТИЧЕСКИХ ПРЕПАРАТОВ |
|
8.4. Фармакогенетика леветирацетама |
vetiracetam, and Perampanel // Behav Neurol. 2018. |
(SLC6A2) in ADHD: Relation to Maternal Smoking during |
|
doi:10.1155/2018/2064027. |
Pregnancy // PLoS ONE. 2012; 7(11): e49616. doi:10.1371/ |
|
56.\ Miyazaki I., Murakami S., Torigoe N., Kitamura Y., |
journal.pone.0049616. |
|
Asanuma M. Neuroprotective effects of levetiracetam target |
69.\ Горина А.С., Кулинский В.И., Колесниченко Л.С., |
|
xCT in astrocytes in parkinsonian mice //J Neurochem. 2016 |
Михнович В.И. Изменения содержания триптофана и |
|
Jan; 136(1):194-204. doi:10.1111/jnc.13405. |
его метаболитов у детей с ранним детским аутизмом. |
|
57.\ Hill M.P., Bezard E., McGuire S.G., Crossman A.R., |
Бюллетень СО РАМН. 2010. № 30 (5). С. 19–24. |
|
Brotchie J.M., Michel A. et al. Novel antiepileptic drug leve- |
70.\ Wigner P., Czarny P., Synowiec E., Bijak M., Białek |
|
tiracetam decreases dyskinesia elicited by L-dopa and rop- |
K., Talarowska M. et al. Association between single nucleo- |
|
inirole in the MPTP-lesioned marmoset // Mov Disord. 2003 |
tide polymorphisms of TPH1 and TPH2 genes, and depres- |
|
Nov; 18(11):1301-5. doi:10.1002/mds.10542. |
sive disorders // J. Cell Mol. Med. 2018; 22: 1778–1791. |
|
58.\ Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., |
doi:10.1111/jcmm.13459. |
|
Zhang H.Z., Peterson M.R. et al. Abnormal neurotransmission |
71.\ Craig, Wendy & Harel-Fisch, Yossi & Fogel-Grin- |
|
in mice lacking synaptic vesicle protein 2A (SV2A) // Proc. |
vald, Haya & Dostaler. et al.. A cross-national profile of bul- |
|
Natl. Acad. Sci. USA. 1999; 96: 15268–15273. doi:10.1073/ |
lying and victimization among adolescents in 40 countries // |
|
pnas.96.26.15268. |
International journal of public health. 2009; 54 (2). 216-224. |
|
59.\ Iezzi M., Theander S., Janz R., Loze C., Wollheim |
doi:10.1007/s00038-009-5413-9. |
|
C.B. SV2A and SV2C are not vesicular Ca2+ transporters but |
72.\ Nielsen D. A tryptophan hydroxylase gene marker |
|
control glucose-evoked granule recruitment. // J. Cell Sci. |
for suicidality and alcoholism // Arch Gen Psychiatry. 1998; |
|
2005; 118, 5647–5660. doi:10.1242/jcs.02658. |
55: 593-602. doi:10.1001/archpsyc.55.7.593. |
|
60.\ Tomson T. Gender aspects of pharmacokinetics of |
73.\ Smith R.M., Papp A.C., Webb A., Ruble C.L., Mun- |
|
new and old AEDs: Pregnancy and breast-feeding // Thera- |
sie L.M., Nisenbaum L.K. et al. Multiple regulatory variants |
|
peutic Drug Monitoring. 2005; 27:718–721. doi:10.1097/01. |
modulate expression of 5-hydroxytryptamine 2A receptors |
|
ftd.0000179843.63515.8f. |
in human cortex // Biol Psychiatry. 2013 Mar 15; 73(6):546- |
|
61.\ Strolin Benedetti M., Whomsley R., Nicolas J.M., |
554. doi:10.1016/j.biopsych.2012.09.028. |
|
Young C., Baltes E. Pharmacokinetics and metabolism of |
74.\ Mendoza-Torreblanca J.G., Vanoye-Carlo A., |
|
14C-levetiracetam, a new antiepileptic agent, in healthy |
Phillips-Farfan B.V. et al. Synaptic vesicle protein 2A: basic |
|
volunteers // Eur J Clin Pharmacol. 2003; 59:621–630. |
facts and role in synaptic function // Eur J Neurosci. 2013; |
|
doi:10.1007/s00228-003-0655-6. |
38:3529–39. doi:10.1111/ejn.12360. |
|
62.\ Cramer J.A., De Rue K., Devinsky O., Edrich P., |
75.\ |
Tokudome K., Okumura T., Shimizu S., Mashimo |
Trimble M.R. A systematic reviewof the behavioral effects of |
T., Takizawa A., Serikawa T.et al. .Synaptic vesicle glycopro- |
|
levetiracetam in adults with epilepsy, cognitive disorders, or |
tein 2A (SV2A) regulates kindling epileptogenesis via GAB- |
|
anxiety disorder during clinical trials // Epilepsy Behav. 2003; |
Aergic neurotransmission // Sci Rep. 2016 Jun 6; 6:27420. |
|
4(2):124–32. doi:10.1016/s1525-5050(03)00005-2. |
doi:10.1038/srep27420. |
|
63.\ Mula M., Trimble M.R., Yuen A., Liu R.S, Sand- |
76.\ Wang D., Zhou Q., Ren L., Lin Y., Gao L., Du J.et al. |
|
er J.W. Psychiatric adverse events during levetiracetam |
Levetiracetam-induced a new seizure type in a girl with a nov- |
|
therapy // Neurology. 2003; 61(5):704–6. doi.:10.1212/01. |
el SV2A gene mutation // Clinical Neurology and Neurosur- |
|
wnl.0000078031.32904.0d. |
gery. 2019. doi:10.1016/j.clineuro.2019.03.020. |
|
64.\ Craig I., Halton K. Genetics of human aggressive |
77.\ |
Serajee F.J., Huq A.M. Homozygous Mutation in |
behavior // Hum Genet. 2009; 126:101-113. doi:10.1007/ |
Synaptic Vesicle Glycoprotein 2A Gene Results in Intracta- |
|
s00439-009-0695-9. |
ble Epilepsy, Involuntary Movements, Microcephaly, and |
|
65.\ Gong P., Liu J., Li S. et al. Dopamine beta-hydrox- |
Developmental and Growth Retardation // Pediatr Neu- |
|
ylase gene modulates individuals’ empathic ability // Social |
rol. 2015 Jun; 52(6):642-651. doi:10.1016/j.pediatrneu- |
|
Cognitive and Affective Neuroscience. 2014; 9(9):1341-1345. |
rol.2015.02.011. |
|
doi:10.1093/scan/nst122. |
78.\ Yang T.W., Moon J., Kim T.J., Jun J.S., Lim J.A., Lee |
|
66.\ Stelzel C., Basten U., Montag C. et al. Frontostriatal |
S.T. et al. HLA-A*11:01 is associated with levetiracetam-in- |
|
involvement in task switching depends on genetic differenc- |
duced psychiatric adverse events // PLoS ONE. 2018; 13(7) |
|
es in d2 receptor density // J Neurosci. 2010; 30:14205-12. |
doi:10.1371/journal.pone.0200812. |
|
doi:10.1523/jneurosci.1062-10.2010. |
79.\ Yun J., Adam J., Yerly D., Pichler W.J. Human leu- |
|
67.\ Savitz J., Hodgkinson C.A., Martin-Soelch C. et al. |
kocyte |
antigens (HLA) associated drug hypersensitivi- |
DRD2/ANKK1 Taq1A polymorphism (rs1800497) has op- |
ty: consequences of drug binding to HLA // Allergy. 2012; |
|
posing effects on D2/3 receptor binding in healthy controls |
67(11):1338±46. doi:10.1111/all.12008. |
|
and patients with major depressive disorder // Int J Neu- |
80.\ Hu F.Y., Wang W., Ren J.C., An D.M., Chen J.N., |
|
ropsychopharmacol. 2013; 16(9):2095-2101. doi:10.1017/ |
Zhou D. Levetiracetam-induced cutaneous adverse |
|
s146114571300045x. |
drug reactions were not associated with HLA genes in a |
|
68.\ Thakur G.A., Sengupta S.M., Grizenko N., |
small sample of Chinese patients with epilepsy // Epi- |
|
Choudhry Z., Joober R.. Comprehensive Phenotype/Gen- |
lepsy Res. 2016 Aug; 124:12-15. doi:10.1016/j.eplep- |
|
otype Analyses of the Norepinephrine Transporter Gene |
syres.2016.04.008. |
305
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/
Глава 8. ФАРМАКОГЕНЕТИКА ПРОТИВОЭПИЛЕПТИЧЕСКИХ ПРЕПАРАТОВ |
|
|
|
|
|
8.6. Фармакогенетика препаратов лития |
|||||
10.\ Goh E.T., Morgan M.Y. Review article: pharmaco- |
22.\ |
Albsoul-Younes A.M., Salem H.A., |
Ajlouni S.F., |
||||||||
therapy for alcohol dependence - the why, the what and the |
Al-Safi S.A. Topiramate slow dose titration: improved effica- |
||||||||||
wherefore// Aliment Pharmacol Ther. 2017 Apr; 45(7):865- |
cy and tolerability // Pediat Neurol. 2004; 31 (5): 349-352. |
||||||||||
882. doi:10.1111/apt.13965. |
doi:10.1016/j.pediatrneurol.2004.04.012. |
|
|||||||||
11.\ Rudenko A., Krupitsky E., Rudenko A., Zvartau E., |
23.\ Abou-KhalilB.Topiramateinthelong-termmanage- |
||||||||||
Slavina T., Grinenko A. The pilot study of topiramate for alco- |
ment of refractory epilepsy. Topiramate YOL Study Group // |
||||||||||
hol with drawal syndrome // Alcohol and Alcoholism. 2003; |
Epilepsia. 2000;41 (1):72-76. doi:10.1111/j.1528-1157.2000. |
||||||||||
38(5): 508-509. |
|
tb02176.x. |
|
|
|
|
|
||||
12.\ |
Brownley K.A., |
Berkman N.D., Peat C.M., Lohr |
24. |
FaughtE.Efficacyoftopiramateasadjunctivetherapy |
|||||||
K.N., Cullen K.E., Bann C.M., Bulik C.M. Binge-Eating Dis- |
in refractory partial seizures: United States trial experience // |
||||||||||
order in Adults: A Systematic Review and Meta-analysis // |
Epilepsia. 1997; 38(1):24-27. doi:10.1111/j.1528-1157.1997. |
||||||||||
Ann Intern Med. 2016 Sep 20;165(6):409-420. doi: 10.7326/ |
tb04513.x. |
|
|
|
|
|
|||||
M15-2455 |
|
|
25.\ Lyseng-Williamson K.A., Yang L.P. Topiramate: a re- |
||||||||
13.\ Abtahi M.A., Abtahi S.H., Fazel F., Roomizadeh P., |
view of its use in the treatment of epilepsy // Drugs. 2007; |
||||||||||
Etemadifar M., Jenab K. et al. Topiramate and the vision: |
67(15):2231-2256. |
|
doi:10.2165/00003495-200767150- |
||||||||
a systematic review // Clin Ophthalmol. 2012; 6:117–131. |
|
||||||||||
00008. |
|
|
|
|
|
|
|||||
doi:10.2147/OPTH.S27695. |
|
|
|
|
|
|
|||||
26.\ Mirza N.S., Alfirevic A., Jorgensen A., Marson A.G., |
|||||||||||
14.\ Costa E. From GABAA receptor diversity emerges a |
|||||||||||
Pirmohamed M. Metabolic |
acidosis with topiramate and |
||||||||||
unified vision of GABA-ergic inhibition // Annu. Rev. Pharma- |
|||||||||||
zonisamide: an assessment of its severity and predictors |
|||||||||||
col. Toxicol. 1998; 38: 321-350. doi:10.1146/annurev.pharm- |
|||||||||||
// Pharmacogenet |
Genomics. 2011 May; 21(5):297-302. |
||||||||||
tox.38.1.321. |
|
|
|||||||||
|
|
doi:10.1097/fpc.0b013e3283441b95. |
|
||||||||
15.\ Chen Y.C., Kung S.S., Chen B.Y., Hung C.C., Chen |
|
||||||||||
27.\ |
Kwan P., Poon W.S., Ng H.K., Kang D.E., Wong |
||||||||||
C.C., Wang T.Y. et al. Identifications, classification, and evo- |
|||||||||||
V., Ng P.W. et al. Multidrug resistance in epilepsy and poly- |
|||||||||||
lution of |
the |
vertebrate |
alpha-amino-3-hydroxy-5-meth- |
||||||||
morphisms in the |
voltage-gated sodium channel genes |
||||||||||
yl-4-isoxazole |
propionic |
acid (AMPA) receptor subunit |
|||||||||
SCN1A, SCN2A, and SCN3A: correlation among pheno- |
|||||||||||
genes // J. Mol. Evol. 2001; 53(6): 690-702. doi:10.1007/ |
|||||||||||
type, genotype, |
and |
mRNA expression // |
Pharmacoge- |
||||||||
s002390010256. |
|
||||||||||
|
net Genomics. |
2008 |
Nov; |
18(11):989-998. |
doi:10.1097/ |
||||||
16.\ Dodgson S.J., Shank R.P., Maryanoff B.E. Topiramate |
|||||||||||
fpc.0b013e3283117d67. |
|
|
|||||||||
as an inhibitor of carbonic anhydrase isoenzymes // Epilepsia. |
|
|
|||||||||
28.\ |
Ray L.A., |
Miranda |
R.Jr., MacKillop |
J., McGeary |
|||||||
2000; 41(1):5-9. doi:10.1111/j.1528-1157.2000.tb02169.x. |
|||||||||||
J., Tidey J.W., Rohsenow D.J. et al. A preliminary pharma- |
|||||||||||
17.\ Shank R.P., Gardocki J.F., Streeter A.J., Maryanoff |
|||||||||||
cogenetic investigation of adverse events from topiramate |
|||||||||||
B.E. An overview of preclinical aspects of topiromate: phar- |
|||||||||||
in heavy drinkers // Exp Clin Psychopharmacol. 2009 Apr; |
|||||||||||
macology, pharmacokinetics, and mecanisn of action // |
|||||||||||
17(2):122-129. doi:10.1037/a0015700. |
|
||||||||||
Epilepsia. 2000; 41(1): 3-9. doi:10.1111/j.1528-1157.2000. |
|
||||||||||
29.\ Li Q.S., Lenhard J.M., Zhan Y., Konvicka K., Atha- |
|||||||||||
tb02163.x. |
|
|
|||||||||
|
|
nasiou M.C., Strauss R.S. et al. A candidate-gene asso- |
|||||||||
18.\ Ormrod D., McClellan K. Topiramate: a review of its |
|||||||||||
ciation study of topiramate-induced weight loss in obese |
|||||||||||
use in childhood epilepsy // Paediatr Drugs. 2001; 3(4):293- |
|||||||||||
patients with and without type 2 diabetes mellitus // Phar- |
|||||||||||
319. doi:10.2165/00128072-200103040-00006. |
|||||||||||
macogenet Genomics. 2016 Feb; 26(2):53-65. doi:10.1097/ |
|||||||||||
19.\ BenMenachem E. Clinical efficacy of topiramate as |
|||||||||||
addon therapy in refractory partial epilepsy: the European |
fpc.0000000000000185. |
|
|
||||||||
experience // Epilepsia. 1997; 38 (1): 28-30. doi:10.1200/ |
30.\ Hung C.C., Chen P.L., Huang W.M., Tai J.J., Hsieh |
||||||||||
jco.2017.35.15_suppl.11571. |
T.J. et al. Gene-wide tagging study of the effects of com- |
||||||||||
20.\ Bialer M., Doose D.R., Murthy B., Curtin C., Wang |
mon genetic polymorphisms in the α subunits of the GAB- |
||||||||||
S.S., Twyman R.E. et al. Pharmacokinetic interactions of |
A(A) receptor on epilepsy treatment response // Pharma- |
||||||||||
topiramate // Clin Pharmacokinet. 2004; 43(12):763-780. |
cogenomics. 2013 Nov; 14(15):1849-1856. doi:10.2217/ |
||||||||||
doi:10.2165/00003088-200443120-00001. |
pgs.13.158. |
|
|
|
|
|
|||||
21.\ Britzi M., Perucca E., Soback S., Levy R., Fattore |
31.\ |
Kranzler H.R., Armeli S., Feinn R., Tennen H., |
|||||||||
C., Crema F. et al. Pharmacokinetic and metabolic inves- |
Gelernter J., Covault J. GRIK1 genotype moderates topi- |
||||||||||
tigation of topiramate disposition in healthy subjects in the |
ramate’s effects on daily drinking level, expectations of al- |
||||||||||
absence and in the presence of enzyme induction by car- |
cohol’s positive effects and desire to drink // Int J Neuropsy- |
||||||||||
bamazepine // Epilepsia. 2005; 46: 378–384. doi:10.1111/ |
chopharmacol. 2014; Oct; 17(10):1549-1556. doi:10.1017/ |
||||||||||
j.0013-9580.2005.55204.x. |
s1461145714000510. |
|
|
|
309
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/